Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-CIBLE
2024-511897-64-00Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Regiocit in acute kidney failure (AKF) and kidney failure (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Incidence of filter thrombosis. Started Jul 2023; status: completed.
02
Drugs
Regiocit
03
Conditions
acute kidney failure (AKF)kidney failure
Beyond the preview
Go deeper on 2024-511897-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511897-64-00.